© 2020 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.
Tecentriq plus Avastin improved improved overall survival and patient experiences during treatment.
Stella Armstrong’s journey to a healthier life wasn’t easy.
Between August 2018 and January 2019, the FDA doubled the number of liver cancer treatments.
With the approval of Cyramza, there are now five targeted therapies for hepatocellular carcinoma.
Twice as many patients were alive 18 months after starting treatment.
Recommendations now include multiple systemic medications in addition to surgery and local therapies.
Latest version of legislation to bypass FDA oversight must now to go back to the Senate.
Immunotherapy had a low response rate, but most responders continue to do well.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.
